

SUPPLEMENTAL MATERIAL

Table S1. Characteristics of patients missing 6-month follow-up

	Overall (n=7347)	Patients with Follow-up (n=6540)	Patients without Follow- up (n=807)	p-Value
OAC+ASA	35	35	30	0.003
Age	75 (68-82)	76 (68-82)	74 (66-81)	0.02
Female	43	43	40	0.1
Race				0.02
White	89	89	87	
Black or African American	4.8	4.5	6.9	
Hispanic	4.5	4.5	4.3	
Past Medical History				
Smoking	48	49	43	0.002
Hypertension	85	85	83	0.2
Hyperlipidemia	72	73	66	<0.0001
Diabetes	30	30.1	30.4	0.9
Obstructive Sleep Apnea	18.5	18.9	15.7	0.03
Heart Failure	34	34	30	0.02
Gastrointestinal Bleeding	7.8	8.0	6.6	0.2
Anemia	17	18	14	0.02
Chronic Obstructive Pulmonary Disease	16	16	14	0.1
Hemoglobin (g/dl)	13.5 (12.3- 14.6)	13.5 (12.3-14.6)	13.5 (12.3- 14.8)	0.6
Calculated creatinine clearance (mL/min/1.73m ²)*	70 (51-97)	70 (51-96)	70 (50-101)	0.4
LVEF (%), mean (SD)	54.3 (12)	54.3 (12)	54.4 (12)	0.7
CHADS ₂ Score				0.02
0	4.6	4.6	5.1	
1	21	20	24	
>2	75	75	71	
CHA ₂ DS ₂ -VASa Score				0.07
0	1.3	1.2	1.6	
1	5.4	5.3	6.2	
>2	85	86	81	
ATRIA Score				0.003
Low (0-3)	75	75	71	
Intermediate (4)	8.6	8.2	11	
High (5+)	17	17	18	
Any Vascular History (CAD, PAD, or CVD)	45	45	43	0.3
CAD				

	Overall (n=7347)	Patients with Follow-up (n=6540)	Patients without Follow- up (n=807)	p-Value
Prior MI	14	14	13	0.2
Prior CABG	14	14	13	0.3
Prior PCI	14	15	13	0.1
Prior DES	4.7	4.7	4.3	0.6
Prior Cerebrovascular Events (stroke or TIA)	16	16	17	0.4
Stroke – non-hemorrhagic	8.7	8.5	9.8	0.2
Stroke – hemorrhagic	0.6	0.5	1.0	0.1
TIA	8.7	8.7	8.8	1.0

Baseline characteristics, co-morbidities, admission data, and laboratory studies, stratified by availability of follow-up.

Values are presented as % or median (interquartile range).

OAC+ASA: oral anticoagulation and aspirin therapy; LVEF: left-ventricular ejection fraction;

CAD: coronary artery disease; MI: myocardial infarction; CABG: coronary artery bypass grafting;

PCI: percutaneous coronary intervention; DES: drug-eluting stent; TIA: transient ischemic attack.